B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells are the most
potent treatment against multiple myeloma (MM). Here, we review the increasing body of …

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several
haematological malignancies and is being investigated in patients with various solid …

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are
intended to provide oncology practitioners with guidance on how to manage the wide …

We report a first-in-human clinical trial using chimeric antigen receptor (CAR) T cells
targeting CD37, an antigen highly expressed in B-and T-cell malignancies. Five patients …

Ciltacabtagene autoleucel (cilta-cel) was approved in 2022 for patients with
relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the …

Multiple myeloma (MM) is a rarely curable malignancy of plasma cells. MM expresses B cell
maturation antigen (BCMA). We developed a fully human anti-BCMA chimeric antigen …

Chimeric antigen receptor (CAR) T cell therapies have dramatically improved treatment
outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, large …

Introduction Despite remarkable therapeutic advances over the last two decades, which
have resulted in dramatic improvements in patient survival, multiple myeloma (MM) is still …

Multiple myeloma is an incurable plasma cell malignancy that evolves over decades through
the selection and malignant transformation of monoclonal plasma cells. The evolution from …

In this issue of Blood, Graham et al 1 and Karschnia et al 2 provide new insights into the rare
hypokinetic movement disorder (also termed movement and neurocognitive treatment …